טוען...
Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy
First-line chemotherapy to combat primary malignant brain cancer is often accompanied by lymphopenic immunologic deficiency. Although counterintuitive, chemotherapy-induced lymphopenia can provide excellent host conditioning that may actually be leveraged to potentiate antitumor immunotherapy. We di...
שמור ב:
| הוצא לאור ב: | Oncoimmunology |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taylor & Francis
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4292586/ https://ncbi.nlm.nih.gov/pubmed/25610727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/21624011.2014.944054 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|